The immuno-oncology drug developer, backed by several pharmaceutical firms, has raised $55m in an IPO that saw it float substantially below its $14 to $16 range.

Agenovir is commercialising technology developed at Stanford University and Howard Hughes Medical Institute that could eliminate currently untreatable viruses.

Roche Venture Fund and 5AM Ventures have joined existing investors including StartX Fund for the oncology diagnostics spinout's $18.2m series A round.

Stanmore Implants is acquired by Stryker Corporation, providing an exit to Imperial Innovations.

Mercia Fund Management backs Bristol University spinout Pertinax Pharma as it begins to scale up the production of its chlorhexidine-based product.

The healthcare group's Toronto incubator is its sixth JLabs site, and is being launched in partnership with University of Toronto and several hospital partners.

Medtronic and Johnson & Johnson-backed Mitralign has so far secured $39.8m in series E funding but has not named the round's investors.